Get the Stockscreener App
1.14
0.00%
0.00
Proqr Therapeutics N V stock is traded at $1.14, with a volume of 464.85K.
It is up +0.00% in the last 24 hours and down -32.94% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$1.14
Open:
$1.15
24h Volume:
464.85K
Relative Volume:
0.95
Market Cap:
$124.15M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-3.0095
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
+0.88%
1M Performance:
-32.94%
6M Performance:
-74.61%
1Y Performance:
-40.00%
1-Day Range:
$1.10
$1.19
1-Week Range:
$1.08
$1.2644
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.14 | 124.15M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
575,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Altium Capital Management LLC - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Affinity Asset Advisors LLC Purchases New Holdings in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of “Buy” by Brokerages - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
ProQR (PRQR) Strengthens Leadership with New CFO and CMO Appointments | PRQR Stock News - GuruFocus
ProQR Strengthens Leadership with Appointments of CFO and CMO to - GuruFocus
ProQR names new CFO and CMO to bolster RNA editing platform By Investing.com - Investing.com South Africa
ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34% - simplywall.st
ProQR names new CFO and CMO to bolster RNA editing platform - Investing.com Canada
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth - GlobeNewswire
ProQR strengthens leadership team - The Pharma Letter
ProQR Therapeutics CFO Jurriaan Dekkers Steps Down, Dennis Hom To Succeed; Cristina Lopez Named CMO - Nasdaq
ProQR's Leadership Overhaul: New CFO Raised $4.5B, Led $57B in Deals - Stock Titan
American Century Companies Inc. Invests $237,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Prudential Financial Inc. - Defense World
Raymond James Financial Inc. Acquires Shares of 97,928 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Virtu Financial LLC Buys New Stake in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Chardan Capital Issues Optimistic Forecast for PRQR Earnings - MarketBeat
FY2025 EPS Estimate for ProQR Therapeutics Lifted by Analyst - Defense World
28,903 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by PNC Financial Services Group Inc. - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $9.50 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives $9.50 Average Target Price from Analysts - The AM Reporter
Privium Fund Management B.V. Sells 646,755 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Platinum Investment Management Ltd. Makes New $4.08 Million Investment in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Brokerages - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Chardan Capital - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for ProQR Therapeutics (NASDAQ:PRQR) Stock - MarketBeat
H.C. Wainwright raises ProQR stock target to $12, maintains Buy By Investing.com - Investing.com Australia
H.C. Wainwright raises ProQR stock target to $12, maintains Buy - Investing.com India
ProQR Therapeutics (NASDAQ:PRQR) Issues Quarterly Earnings Results - MarketBeat
Chardan Capital Reaffirms Buy Rating for ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Raymond James maintains Strong Buy on ProQR stock, $14 target By Investing.com - Investing.com Australia
Raymond James maintains Strong Buy on ProQR stock, $14 target - Investing.com India
ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com
ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com South Africa
Proqr Therapeutics NV Files For Shelf Of Up To Up To 3.5 Million Ordinary Shares By Selling StockholderSEC Filing - Marketscreener.com
SEC Form 20-F filed by ProQR Therapeutics N.V. - Quantisnow
ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Key Milestones Set for 2025 - Nasdaq
ProQR Announces Year End 2024 Operating and Financial Results - GlobeNewswire
ProQR Secures 3-Year Runway with €149M War Chest, 4 Clinical Readouts Coming - StockTitan
| MarketBeat - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Upgraded at Citigroup - MarketBeat
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):